Esperante Ventures
Overview
Esperante Ventures is a Netherlands-based corporate venture capital firm specializing in investments in therapeutics and diagnostics companies during late preclinical or clinical development stages. The firm focuses on opportunities in Europe and North America, aiming to support the growth of innovative healthcare solutions. Established in 2004, Esperante Ventures has built a diverse portfolio of companies across various countries, including the United States, United Kingdom, Netherlands, Israel, and France. Their investment strategy encompasses a range of stages, from pre-seed to Series C and beyond, with typical investments ranging from €100,000 to €2,000,000. The firm's leadership brings decades of cross-functional management experience in the human healthcare industry, providing portfolio companies with extended management resources, particularly in business development. This expertise complements their financial contributions, aiming to accelerate the growth and success of their investee companies.
Investment Focus
- Late preclinical or clinical development phase
- Focus on therapeutics and diagnostics
- Presence in Europe or North America
Portfolio Companies
Reach Esperante Ventures directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about Esperante Ventures
What sectors does Esperante Ventures invest in?
Esperante Ventures invests in Healthcare, Pharmaceuticals, Diagnostics and Biotechnology, and is based in Netherlands. Esperante Ventures is listed as a corporate vc in the ConnectSafely investor database.
What stage does Esperante Ventures invest at?
Esperante Ventures backs companies at Pre-Seed, Seed, Series A and Series B, writing cheques of 100K - 2M.
Which regions does Esperante Ventures invest in?
Esperante Ventures invests across United States, United Kingdom, France, Netherlands and Israel.
What companies has Esperante Ventures invested in?
Esperante Ventures's portfolio includes Altacor, Cara Therapeutics, Arno Therapeutics, Canbex Therapeutics, Immune Targeting Systems, Karus Therapeutics, Novacta Biosystems and Theryte.
Last updated · Source: ConnectSafely investor database
